KDx Diagnostics Inc.

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.

• Employees11
• Founded2016
• Total Funding$865000